SERA [NASD]
Sera Prognostics, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own0.30% Shs Outstand30.80M Perf Week-1.33%
Market Cap45.76M Forward P/E- EPS next Y-1.51 Insider Trans-25.63% Shs Float21.53M Perf Month-33.63%
Income-40.90M PEG- EPS next Q-0.37 Inst Own55.10% Short Float1.31% Perf Quarter-73.33%
Sales0.10M P/S457.62 EPS this Y-76.40% Inst Trans2.28% Short Ratio3.34 Perf Half Y-86.47%
Book/sh4.13 P/B0.36 EPS next Y2.50% ROA-30.80% Target Price10.33 Perf Year-
Cash/sh3.48 P/C0.43 EPS next 5Y- ROE-58.40% 52W Range1.43 - 15.50 Perf YTD-78.46%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-90.45% Beta-
Dividend %- Quick Ratio15.80 Sales past 5Y- Gross Margin51.40% 52W Low3.50% ATR0.21
Employees115 Current Ratio15.80 Sales Q/Q333.30% Oper. Margin- RSI (14)24.34 Volatility8.03% 11.55%
OptionableNo Debt/Eq0.01 EPS Q/Q-90.20% Profit Margin- Rel Volume3.29 Prev Close1.52
ShortableYes LT Debt/Eq0.01 EarningsMay 10 AMC Payout- Avg Volume84.24K Price1.48
Recom1.80 SMA20-22.50% SMA50-43.19% SMA200-79.69% Volume277,038 Change-2.63%
Mar-30-22Downgrade Citigroup Buy → Neutral $18 → $4
Nov-19-21Initiated Oppenheimer Outperform $19
Oct-15-21Resumed Cowen Outperform
May-19-22 04:15PM  
May-18-22 03:03PM  
May-10-22 04:05PM  
May-05-22 08:30AM  
May-02-22 08:30AM  
Apr-12-22 08:30AM  
Mar-30-22 07:30AM  
Mar-29-22 04:00PM  
Mar-18-22 12:00PM  
07:00AM  
Mar-03-22 08:30AM  
Feb-17-22 08:30AM  
Feb-07-22 08:30AM  
Feb-01-22 08:30AM  
Dec-15-21 08:30AM  
Dec-02-21 08:00AM  
Dec-01-21 11:40AM  
Nov-30-21 08:00AM  
Nov-10-21 09:01AM  
Nov-09-21 04:01PM  
Nov-08-21 04:20PM  
Nov-04-21 08:00AM  
Nov-03-21 08:00AM  
Nov-02-21 08:00AM  
Oct-27-21 08:30AM  
Oct-15-21 10:59AM  
Sep-28-21 08:30AM  
Sep-20-21 08:30AM  
Sep-15-21 08:00AM  
Sep-14-21 08:00AM  
Sep-13-21 08:00AM  
Aug-30-21 04:05PM  
Aug-17-21 08:00AM  
Jul-14-21 09:03PM  
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boniface John J.Chief Scientific OfficerMay 24Sale1.542,7254,19671,035May 24 06:16 PM
Boniface John J.Chief Scientific OfficerMay 17Sale1.552,7254,22473,760May 17 06:41 PM
Boniface John J.Chief Scientific OfficerMay 10Sale1.972,7255,36876,485May 10 06:47 PM
Boniface John J.Chief Scientific OfficerMay 04Option Exercise0.731,00073080,210May 04 06:15 PM
Boniface John J.Chief Scientific OfficerMay 04Sale2.171,0002,17079,210May 04 06:15 PM
Boniface John J.Chief Scientific OfficerMay 03Sale2.172,7255,91379,210May 03 05:43 PM
Boniface John J.Chief Scientific OfficerApr 26Sale2.172,7255,91381,935Apr 26 06:28 PM
Boniface John J.Chief Scientific OfficerApr 19Sale2.082,7255,66884,660Apr 20 04:36 PM
Boniface John J.Chief Scientific OfficerApr 12Sale2.662,7257,24887,385Apr 13 04:26 PM
Boniface John J.Chief Scientific OfficerApr 06Option Exercise0.731,00073091,110Apr 07 04:09 PM
Boniface John J.Chief Scientific OfficerApr 06Sale3.021,0003,02090,110Apr 07 04:09 PM
Boniface John J.Chief Scientific OfficerApr 05Sale3.352,7259,12990,110Apr 07 04:09 PM
Boniface John J.Chief Scientific OfficerMar 29Sale3.732,72510,16492,835Mar 30 04:07 PM
Boniface John J.Chief Scientific OfficerMar 22Sale3.682,72510,02895,560Mar 23 04:11 PM
Boniface John J.Chief Scientific OfficerMar 14Sale3.942,72510,73698,285Mar 15 05:58 PM
Boniface John J.Chief Scientific OfficerMar 11Option Exercise0.7375,99855,479101,010Mar 14 04:16 PM
Boniface John J.Chief Scientific OfficerDec 06Option Exercise0.7325,01218,25925,012Dec 06 09:15 PM